RE: Jumping ship27 Oct 2025 20:17
RNS June 14 2024
ntellectual Property ("IP") encompasses a diverse array of forms, such as data, dosing schema, biomarkers or diagnostic parameters, various methods of delivery, etc. We are acutely aware of the value IP has and are exploring potential mechanisms to strengthen our position. In our possession today are exclusive rights to phase 1 trial data and imminently the EAP data. Post approval, we will take full advantage of the seven years' market exclusivity offered by Orphan Drug Designation, which allows sponsors to sell the drug without competition. We intend to invest to strengthen IP during the seven-year market exclusive period including formulation improvements, delivery alternatives, and combination treatments.
Thanks